Clinical trials: 5-FU, completed
Colorectal Cancer
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.
- Trial name
- NCT00003950
- Testing
- cyclosporine, CPT-11
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Chemotherapy Effect
Feasibility and Safety of Neoadjuvant Chemotherapy (FLOT ) for Gastric Cancer Patients in China
Neoadjuvant chemotherapy for advanced-stage gastric cancer is justified by various studies, however, there was not any large scale randomized controlled trial (RCT) to support it until German oncologist introduced a novel…
- Trial name
- NCT03646591
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Cancer
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative…
- Trial name
- PIER (NCT03000374)
- Testing
- Panitumumab, 5Fluorouracil, Oxaliplatin
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Gastric Cancer, Gastroesophageal Junction Cancer
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
This is a Phase 2/3, randomized, open-label study for the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer conducted in two parts.
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
- Trial name
- MAHOGANY (NCT04082364)
- Testing
- margetuximab, Retifanlimab, Tebotelimab
- Where
- 73 sites in United States, China and 7 more
- Volunteers
- 82 people
- Sponsor
- MacroGenics
Adenocarcinoma of the Colon, Stage III Colon Cancer
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003835
- Testing
- leucovorin calcium, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 1,260 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasms
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU.
- Trial name
- NCT00349076
- Testing
- 5-FU and oxaliplatin, 5-FU
- Where
- 89 sites in Germany
- Volunteers
- 1,256 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Colorectal Cancer
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the…
- Trial name
- NCT01442935
- Testing
- Oxaliplatin, Folinic Acid, 5-FU
- Where
- France
- Volunteers
- 256 people
- Sponsor
- UNICANCER
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Esophageal Cancer
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in Pre-treated patients…
- Trial name
- NCT00209716
- Testing
- Taxotere, 5-Fluorouracil, Briplatin
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Pregnancy, Neonates
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
The objective of follow-up study P05713 is to evaluate whether corifollitropin alfa (Org 36286) treatment for the induction of monofollicular growth in women who underwent ovulation induction (OI) in base study P05693…
- Trial name
- Care (NCT00702338)
- Testing
- corifollitropin alfa, recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG)
- Volunteers
- 1 people
- Sponsor
- Organon and Co
Pancreatic Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with…
- Trial name
- NCT03193190
- Testing
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin
- Where
- 23 sites in United States, Germany and 3 more
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Head and Neck Cancer
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00054054
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 95 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Rectal Carcinoma
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical…
- Trial name
- NCT00682786
- Testing
- 5FU, Radiation, Surgery of resectable lesions
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer Metastatic
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
- Trial name
- NCT03251612
- Testing
- Based on sensitivity analysis
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 90 people
- Sponsor
- Vejle Hospital
Esophageal Cancer, Gastric Cancer
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Anti-angiogenic therapy is a proven therapeutic target in refractory gastric and gastroesophageal junction adenocarcinoma. This trial assessed whether the addition of a high affinity angiogenesis inhibitor, ziv-aflibercept, could…
- Trial name
- NCT01747551
- Testing
- Oxaliplatin, Leucovorin, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer, Gastric Cancer
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
The purpose of this study is to evaluate the effects, good and/or bad, of the drug regorafenib with chemotherapy regime (FOLFOX).
- Trial name
- NCT01913639
- Testing
- Regorafenib, 5-Fluorouracil, Leucovorin
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
- Trial name
- CheckMate 651 (NCT02741570)
- Testing
- Nivolumab, Ipilimumab, Cetuximab/Erbitux
- Where
- 133 sites in United States, Australia and 16 more
- Volunteers
- 947 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.